These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 9617505)

  • 21. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
    Brocco M; Dekeyne A; Papp M; Millan MJ
    Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
    Piercey MF; Hyslop DK; Hoffmann WE
    Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
    Le WD; Jankovic J; Xie W; Appel SH
    J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
    Malik P; Andersen MB; Peacock L
    Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
    Black KJ; Hershey T; Koller JM; Videen TO; Mintun MA; Price JL; Perlmutter JS
    Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17113-8. PubMed ID: 12482941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
    Millan MJ; Maiofiss L; Cussac D; Audinot V; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2002 Nov; 303(2):791-804. PubMed ID: 12388666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
    McCormick PN; Fletcher PJ; Wilson VS; Browne JD; Nobrega JN; Remington GJ
    Neuropharmacology; 2015 Feb; 89():225-31. PubMed ID: 25283483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease.
    McCall RB; Lookingland KJ; Bédard PJ; Huff RM
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1248-56. PubMed ID: 15980060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
    Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
    Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
    Merlo S; Canonico PL; Sortino MA
    Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.